Pages

Tuesday, March 13, 2018

Intec Pharma Partners with LTS for Parkinson's

March 13, 2018



Intec Pharma has partnered with LTS Lohmann Therapie-Systeme AG ("LTS") for the manufacture of Intec’s lead product candidate, Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) as a treatment for the severe symptoms in advanced Parkinson's Disease patients. 

Under the agreement, LTS will manufacture the AP-CD/LD capsules using Intec's proprietary Accordion Pill production technology in LTS' manufacturing facility in Andernach, Germany upon the completion of assembly of the production line. 
Currently, Intec is producing the AP-CD/LD capsules for its Phase 3 clinical trial at its existing manufacturing facility in Jerusalem and will work together with LTS to establish commercial scale production capabilities for AP-CD/LD capsules.

"We are particularly pleased to be partnering with LTS, a global leader in the commercial manufacture of formulation and film technologies for the pharmaceutical industry. This is a key achievement for Intec as we near completion of our pivotal Phase 3 ACCORDANCE clinical trial in advanced Parkinson's Disease patients and advance our pre-commercial strategies for AP-CD/LD," said Jeffrey A. Meckler, chief executive officer of Intec Pharma.

"LTS is highly committed to contribute to the innovative opportunities of the Accordion Pill technology for Carbidopa/Levodopa. LTS´ well proven capabilities in the scale-up and large volume manufacture meet Intec´s requirements for a reliable supply that conforms with the most stringent quality requirements," commented Michael Hoffmann, chief technology and operating Officer of LTS.

In addition to securing commercial scale manufacturing for AP-CD/LD, Intec has made other inroads advancing its pre-commercial strategy. In recent months, Intec has enhanced its leadership with a number of key hires and initiated an in-depth market access analysis of the potential for AP-CD/LD in the Parkinson's Disease market. Initial results of the market analysis indicate there is a substantial market for AP-CD/LD to potentially serve hundreds of thousands of patients suffering with Parkinson's Disease.  
 
https://www.contractpharma.com/contents/view_breaking-news/2018-03-13/intec-pharma-partners-with-lts-for-parkinsons/
SaveSave

No comments:

Post a Comment